RMED VS XRTX Stock Comparison

Performance

RMED
10/100

RMED returned -95.79% in the last 12 months. Based on SPY's performance of -8.73%, its performance is below average giving it a score of 10 of 100.

XRTX
100/100

XRTX returned 164.84% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

RMED
75/100

4 analysts offer 12-month price targets for RMED. Together, they have an average target of 0, the most optimistic target put RMED at 0 within 12-months and the most pessimistic has RMED at 0. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

XRTX

"Analyst Price Targets" not found for XRTX

Technicals

RMED
11/100

RMED receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

XRTX
89/100

XRTX receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

Earnings

RMED
10/100

RMED has missed earnings 12 times in the last 20 quarters.

XRTX
100/100

XRTX has missed earnings 1 times in the last 20 quarters.

Profit

RMED
10/100

Out of the last 20 quarters, RMED has had 0 profitable quarters and has increased their profits year over year on 0 of them.

XRTX
10/100

Out of the last 20 quarters, XRTX has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

RMED
44/100

RMED has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

XRTX
49/100

XRTX has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Ra Medical Systems, Inc Summary

Healthcare

Medical Devices

Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.

XORTX Therapeutics Inc. Common Stock Summary

Nasdaq / XRTX

Healthcare

Biotechnology

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

Power up your portfolio